Neonatal Abstinance Score.

<p>Modified from Finnegan to Swedish, (Sarman 2000) here re-translated.</p

Neonatal characteristics of infants exposed to antidepressants in utero, born 1 Jan 2007 to 30 June 2009 at Karolinska University Hospital.

<p>*gestational age <37+0.</p><p>**other antidepressants (n = 33): escitalopram (13 patients), venlafaxine (11), paroxetine (8) and duloxetine (1).</p>†<p>p 0.02, statistical test (logistic regression, adjusting for gestational age, maternal tobacco use, infant sex and 5 min Apgar).</p><p>Neonatal characteristics of infants exposed to antidepressants in utero, born 1 Jan 2007 to 30 June 2009 at Karolinska University Hospital.</p

Characteristics of study population, women with antidepressant treatment and delivery at Karolinska University Hospital Huddinge Jan 2007 to June 2009.

≠<p>one patient can have more than one diagnosis.</p>≠≠<p>other psychiatric diagnoses, all antidepressants (n): Phobia (4), Post-traumatic stress disorder (4), Eating disorder (9), Personality disorder (6), Obsessive compulsive disorder (7), Bipolar disorder type II (1), Attention deficit hyperactivity disorder (3).</p><p>*stated by mother at interview with midwife in prenatal care center, gestational week 10–14.</p><p>**other antidepressants (n = 33): escitalopram (13 patients), venlafaxine (11), paroxetine (8) and duloxetine (1).</p><p>***Highest dose in maternal care records during third trimester.</p><p>NA  =  not applicable.</p><p>Characteristics of study population, women with antidepressant treatment and delivery at Karolinska University Hospital Huddinge Jan 2007 to June 2009.</p

Analyses of Neonatal Abstinence Score in infants exposed to antidepressants in utero, born at Karolinska University Hospital Huddinge 1 Jan 2007 to 30 June 2009.

<p>*two or more scorings of 4–7.</p><p>**two or more scorings of 8 or above.</p><p>***Multiple ordinal regression, adjusted for infant sex and 5 min Apgar.</p>†<p>Chi square test.</p>††<p>Kruskal Wallis.</p>≠<p>other antidepressants (n = 33): escitalopram (13 patients), venlafaxine (11), paroxetine (8) and duloxetine (1).</p><p>Analyses of Neonatal Abstinence Score in infants exposed to antidepressants in utero, born at Karolinska University Hospital Huddinge 1 Jan 2007 to 30 June 2009.</p

Summary of administration information for efavirenz (Stocrin).

<p>Summary of administration information for efavirenz (Stocrin).</p

Distribution of log_e mean efavirenz plasma concentration/(dose/weight) by geographical origin.

<p>Number of patients 36 (African 30, Asian 4, Latin American 2), number of samples 182. Mean, standard deviation and 95% confidence interval are incorporated.</p

Correlation between dose/weight and efavirenz plasma concentration.

<p>Scatterplot visualizing the EFV plasma concentrations from 36 patients with 182 samples and corresponding dose/weight. Linear regression with cluster robust standard errors: P-EFV (mg/L) = 4.34–0.0556*Dose/Weight (mg/kg/day); p = 0.36; r² = 0.0046.</p

Interindividual variability in mean EFV plasma concentrations and mean dose/weight.

<p>Variation in the mean dose/weight (left) and EFV mean plasma concentration (right) in all included patients (n = 36).</p

Relation between genetic variants, age at treatment initiation, time from treatment initiation, sex and log_e EFV plasma concentration/(dose/weight).

<p>Relation between genetic variants, age at treatment initiation, time from treatment initiation, sex and log_e EFV plasma concentration/(dose/weight).</p

Genotype and allele frequency distribution.

<p>Genotype and allele frequency distribution.</p